Hematoporphyrin Derivative: A New Aid for Endoscopic Detection of Malignant Disease

Lipson, Richard L.; Baldes, Edward J.; Olsen, Arthur M.

doi:10.1016/s0022-5223(19)32560-7

Cited by 233 publications

(57 citation statements)

References 4 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…To treat cancer, it has been well-established that the PS functions best when it is injected intravenously into the circulation and allowed to accumulate at the site of the tumor. Indeed, many PS were first clinically tested as fluorescent contrast agents that could "light up" undiscovered tumors in difficult anatomical locations (Lipson, Baldes, & Olsen, 1961;Rassmussan-Taxdal, Ward, & Figge, 1955). In some cases drug-light intervals as long as 96 hr have been allowed to elapse between injection of the PS (mtetrahydroxyphenylchlorin) and switching on the red laser light (D'Cruz, Robinson, & Biel, 2004).…”

Section: Antimicrobial Photodynamic Inactivation (Apdi)mentioning

confidence: 99%

Can light‐based approaches overcome antimicrobial resistance?

Hamblin

Abrahamse

2018

Drug Development Research

View full text Add to dashboard Cite

The relentless rise of antibiotic resistance is considered one of the most serious problems facing mankind. This mini-review will cover three cutting-edge approaches that use light-based techniques to kill antibiotic-resistant microbial species, and treat localized infections. First, we will discuss antimicrobial photodynamic inactivation using rationally designed photosensitizes combined with visible light, with the added possibility of strong potentiation by inorganic salts such as potassium iodide. Second, the use of blue and violet light alone that activates endogenous photoactive porphyrins within the microbial cells. Third, it is used for "safe UVC" at wavelengths between 200 nm and 230 nm that can kill microbial cells without damaging host mammalian cells. We have gained evidence that all these approaches can kill multidrug resistant bacteria in vitro, and they do not induce themselves any resistance, and moreover can treat animal models of localized infections caused by resistant species that can be monitored by noninvasive bioluminescence imaging. Light-based antimicrobial approaches are becoming a growing translational part of anti-infective treatments in the current age of resistance.

show abstract

Section: Antimicrobial Photodynamic Inactivation (Apdi)mentioning

confidence: 99%

Can light‐based approaches overcome antimicrobial resistance?

Hamblin

Abrahamse

2018

Drug Development Research

View full text Add to dashboard Cite

show abstract

“…4 The modern interest in PDT as a treatment modality for cancer therapy began around 1960 with Lipson et al and Schwartz et al, who used a fluorescent tumour-localizing mixture of porphyrins termed 'haematoporphyrin derivative'. 5,6 Since their pioneering work, compounds including photofrin, purpurins, xanthenes, phthalocyanaines, oxazines, cyanines, chlorines and others have been tested in vitro and in vivo with some degree of success; however, in the clinical setting, porphyrins or porphyrin-related compounds continue to form the bulk of the photosensitizers used in PDT. The therapy, as used in cancer treatment, is based on the preferential uptake and/or retention of a photosensitizer in the tumour tissue and the cytotoxic effects of the photosensitizer when activated upon exposure to light.…”

Section: Historical Perspectivementioning

confidence: 99%

Art and Science of Photodynamic Therapy

Pervaiz

Olivo

2006

Clin Exp Pharma Physio

129

View full text Add to dashboard Cite

4. Light sources have moved from the use of white light with specific filters in the old days to the more recent use of monochromatic light sources, such as lasers, to more sophisticated light-emitting diodes. However, dosimetry remains a big issue mainly because of difficulties in establishing the optimum treatment conditions for an approach that requires the finetuning of several variables, such as sensitizer and light doses and drug-to-light interval, as well as the issues of skin photosensitivity and low selectivity. A newer development to circumvent these and provide a broader application for this concept has been the phenomenon of photo-activation, whereby photo-exposure of chromophores to generate novel, small biologically active compounds has been demonstrated successfully.5. The aim of the present review was to provide a general overview of the art and science of photodynamic therapy and to highlight some of the issues and recent developments in further advancing this modality of treatment.

show abstract

“…Soon afterwards, Lipson et aZ. 13) Recently several kinds of new photosensitizers such as aluminium chlorosulphonated phthalocyanine ( A~S P C )~' ) , mesotetra (hydro~yphenyl)porphyrins~~), and mono-Laspartyl chlorin (NPe6)34) have been developed. These new drugs are all superior to Photofrin I1 (DHE) in purity, have higher affinity for malignant tumors and show strong absorption at longer wavelengths.…”

Section: (3) a Review Of Pdtmentioning

confidence: 99%